Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

Abstract Type 2 diabetes (T2D), which has currently become a global pandemic, is a
metabolic disease largely characterised by impaired insulin secretion and action. Significant …

Background Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic
polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response …

With an increasing prevalence of obesity, there is a need for new therapies to improve body
weight management and metabolic health. Multireceptor agonists in development may …

Metabolic homeostasis in mammals is tightly regulated by the complementary actions of
insulin and glucagon. The secretion of these hormones from pancreatic β-cells and α-cells …

Background Treating hyperglycaemia and obesity in individuals with type 2 diabetes using
multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a …

The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …

Obesity contributes to reduced life expectancy, impaired quality of life, and disabilities,
mainly in those individuals who develop cardiovascular diseases, type 2 diabetes …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …